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 Five families with dominant distal and LGMD are presented and clinically described 
 Two novel disease-causing variants in the J domain of DNAJB6 are identified 
 This extends the range of mutations out of the G/F-rich domain. 
 Two independent methods show evidence of functional defects for these mutations 
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Eight patients from five families with undiagnosed dominant distal myopathy underwent 
clinical, neurophysiological and muscle biopsy examinations. Molecular genetic studies 
were performed using targeted sequencing of all known myopathy genes followed by 
segregation of the identified mutations in the affected families using Sanger sequencing. 
Two novel mutations in DNAJB6 J domain, c.149C>T (p.A50V) and c.161A>C (p.E54A), 
were identified as the cause of disease. The muscle involvement with p.A50V was distal 
calf-predominant, and the p.E54A was more proximo-distal. Histological findings were 
similar to those previously reported in DNAJB6 myopathy. In line with reported pathogenic 
mutations in the glycine/phenylalanine (G/F) domain of DNAJB6, both the novel mutations 
showed reduced anti-aggregation capacity by filter trap assay and TDP-43 disaggregation 
assays. Modeling of the protein showed close proximity of the mutated residues with the 
G/F domain. 
Myopathy-causing mutations in DNAJB6 are not only located in the G/F domain, but also 
in the J domain. The identified mutations in the J domain cause dominant distal and 
proximo-distal myopathy, confirming that mutations in DNAJB6 should be considered in 
distal myopathy cases. 
Keywords: DNAJB6 gene, limb-girdle muscular dystrophy, chaperonopathy 
Abbreviations: G/F = glycine/phenylalanine; GFP = green fluorescent protein 
1. Introduction 
Mutations in DNAJB6 were identified in 2012 to cause autosomal dominant limb-girdle 
muscular dystrophy type 1D (LGMD1D, OMIM 603511; current proposed nomenclature 




LGMD D1 DNAJB6-related) [1,2]. Later, several other DNAJB6 mutations have been 
identified in Asian, European and North American populations [3-11]. Interestingly, all 
reported mutations have affected the glycine/phenylalanine-rich (G/F) domain of DNAJB6. 
LGMD1D was originally described as late-onset, slowly progressive disease, most patients 
remained ambulant even at high age. However, some mutations cause an earlier, more 
severe or distal-onset disease [2,5-8,12,13]. 
Muscle pathology in LGMD1D includes protein accumulations followed by autophagic 
rimmed vacuoles. The protein accumulations commonly contain proteins of the sarcomeric 
Z-disk, whereas the rimmed vacuoles are positive for LC3, SQSTM1 and TARDBP 
[2,5,14]. 
DNAJB6 is a member of the HSP40 (J-protein) family of co-chaperones. These co-
chaperones interact with the HSPA (Hsp70) chaperones through their J domains, 
delivering client proteins to HSPAs and stimulating their ATPase activity [15]. DNAJB6 has 
been shown to bind and stimulate HSPA8 (Hsc70) [16,17], but it can also counteract 
protein aggregation in an HSPA-independent manner [18]. The protein accumulations in 
DNAJB6-mutated muscle indicate a reduced ability to handle normally occurring misfolded 
proteins. Indeed, all reported disease-causing DNAJB6 mutations have shown reduced 
anti-aggregation capacity in vitro [1,5,9,19]. 
By using targeted sequencing of muscle disease genes [20,21] we studied families with 
distal myopathies. Here we present evidence of two novel mutations in the J domain of 
DNAJB6 in five separate families as the cause of dominant adult-onset distal and proximo-
distal myopathy. 




2. Patients and methods 
2.1. Study subjects and clinical examinations 
Five families with eight affected patients with unknown distal myopathy were investigated. 
The families were from Spain (Family 1), Norway (Family 2), Italy (Family 3), Finland 
(Family 4) and Japan (Family 5). There were affected family members in two or three 
generations (except for Family 2) showing autosomal dominant inheritance pattern (Fig. 1). 
The patients had been clinically examined, and medical and family histories reviewed by 
neurologists. Electrophysiological examinations consisting of nerve conduction studies and 
needle electromyogram (EMG), creatine kinase (CK) measurements, and in a subset of 
patients pulmonary or cardiac evaluations, were performed. Muscle imaging was available 
from seven and muscle biopsy from six patients.  
In Family 2 the proband was the only affected member; her parents were deceased and 
not available for the study. Her two daughters and one granddaughter were analysed as 
part of the segregation studies. The daughter (F2 III:1) and granddaughter (IV:1) were 
diagnosed with chronic fatigue syndrome. No muscle weakness or atrophy was observed 
on their clinical examination.  
2.2. Standard Protocol Approvals, Registrations and Patient Consents 
The study was approved by the IRB of Tampere University Hospital. All participants 
provided appropriate consent and the study was conducted according to the Helsinki 
Declaration. 
2.3. Genetics 
Genomic DNA was isolated from peripheral blood lymphocytes using standard techniques. 
DNA samples from the probands of Families 1–4 were sequenced using the targeted high-




throughput sequencing panel MYOcap as previously described [20]. The DNA sample 
from the proband of Family 5 was sequenced using the targeted high-throughput 
sequencing panel “myopathy with protein aggregations/rimmed vacuoles” as previously 
described [21]. The identified DNAJB6 variants and the segregation in available family 
members were verified by Sanger sequencing. Primer sequences are available on 
request. Sequence variants in DNAJB6 are described according to the coding DNA 
reference sequence (NG_032573.1), covering DNAJB6 transcript variant-1 
(NM_058246.3). The minor allele frequency (MAF) reported refers to the frequency in 
gnomAD database (http://gnomad.broadinstitute.org) 
2.4. Muscle pathology and antibodies 
Snap-frozen patient muscle biopsies were cryo-sectioned and stained for endogenous 
proteins using antibodies against DNAJB6 (2C11-C1, Novus Biologicals; ab96539, 
Abcam); TIA1 (ab61700, Abcam); TARDBP (TDP-43) (WH0023435M1-1, Sigma-Aldrich); 
SQSTM1 (p62) (P0067, MilliporeSigma), and myotilin (10731-1-A, Proteintech). 
Histological stainings and electron microscopy were performed using standard methods. 
2.5. Structure modelling 
The 3D-structure of wild-type DNAJB6b was modelled using I-TASSER [22-24] and 
visualized using Swiss-PdbViewer v4.1.0 [25] and POV-Ray v3.7. 
2.6. Protein sequence alignment 
Protein sequences of vertebrate DNAJB6 orthologs were retrieved from UniProt 
(https://www.uniprot.org). Multiple sequence alignment of the N-terminal parts of the 
proteins, covering the J and G/F domains, was generated with Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa/clustalo/). 




2.7. Plasmid constructs 
The inducible DNAJB6a wild-type, DNAJB6b wild-type, and DNAJB6b F93L constructs in 
pCDNA5/TO, and 120Q-HTT in pEGFP-N1 have been described previously [1,26]. The 
c.149C>T (p.A50V), c.161A>C (p.E54A), c.170C>T (p.S57L), and c.93T>A (p.H31Q) 
mutations and double mutations were introduced by site-directed mutagenesis. To create 
GFP-DNAJB6b constructs, inserts encoding wild-type and variant DNAJB6b were ligated 
into the pcDNA3.1 vector containing a GFP tag. To create mCherry-TDP-43, full length 
TDP-43 cDNA was cloned into the pCherry-C1 vector. All constructs were verified by 
Sanger sequencing. 
2.8. Filter-trap assay 
The ability of DNAJB6 to prevent aggregation of polyQ-huntingtin was tested using filter-
trap assay as described earlier [1,5,9] with minor modifications. In brief, T-REx 293 cells 
(Invitrogen) were grown at 37 °C, 5% CO2, in DMEM supplemented with 10% fetal bovine 
serum, GlutaMax, penicillin/streptomycin, and blasticidin S. The cells were transfected with 
GFP-tagged 120Q-HTT and inducible V5-tagged DNAJB6-constructs, expression of 
DNAJB6 induced after 5 h (or 4 h in experiments involving p.H31Q constructs) and the 
cells harvested 48 h post transfection. The soluble fraction of 120Q-HTT was measured 
using western blotting and the aggregates trapped in a 0.2 µm cellulose acetate filter 
(Whatman GmbH). The membranes and filters were stained for GFP (A-11122, Invitrogen) 
and V5 (R960-25, Invitrogen), scanned on an Odyssey scanner (LI-COR) and quantified 
using ImageStudio v. 3.1.4 (LI-COR) or ImageJ. The aggregation score was calculated 
from the intensities of aggregated and soluble GFP-HTT as 
(aggregated/soluble)induced/(aggregated/soluble)uninduced and statistical significance 
calculated using a two-tailed Mann-Whitney U-test without multiple testing correction. 




2.9. TDP-43 aggregation assay 
The TDP-43 aggregation assay has been described previously [19,27]. In brief, U2OS 
cells were transfected with wild-type or variant GFP-DNAJB6b constructs together with 
mCherry-TDP-43. After 24 hours, the cells were heat-shocked at 42°C for 1 h prior to 
fixing. The proportion of cells containing mCherry-TDP-43 aggregates was determined by 
fluorescence microscopy. For each condition at least 300 cells were counted by a blinded 
assessor and the experiment repeated three times. Statistical significance was calculated 
using a two-tailed t-test without multiple testing correction. 
2.10. Data availability statement 
The data that support the findings of this study are available from the corresponding 
author, upon reasonable request. 
3. Results 
3.1. Clinical features 
The probands of Families 1–4 had distal lower leg weakness and findings compatible with 
distal myopathy. Two patients (F3 I:2 and III:2) carrying the DNAJB6 mutation were 
subjectively asymptomatic. However, objectively F3 III:2 had mild but clear typical findings 
on muscle MRI and slightly limping gait. F3 I:2 was not available for investigation. The 
mean age of onset was 48 years. The patients had difficulties in walking and especially 
walking on toes as a first sign. The symptoms were slowly progressive. There was muscle 
atrophy in the feet and calf muscles, and later in the hands with mild upper limb weakness. 
The probands of Family 1 (II:1) and 3 (II:1) also had proximal lower limb weakness 
resulting in difficulties in climbing stairs or rising from chair. One patient had mild 
dysphagia, others had no bulbar symptoms or facial muscle weakness.  




The proband of Family 5 had more pronounced lower limb weakness causing difficulties in 
walking, climbing stairs and tendency to fall. On examination he had both proximal and 
distal lower limb weakness. He had also Achilles tendon contractures and decreased 
tendon reflexes. His mother had mild proximal and distal muscle weakness and dysarthria 
but was not available for further examination. 
CK levels were normal or slightly elevated in all patients and EMG showed myopathic 
changes especially in the distal limb muscles. Clinical details of the patients are presented 
in table 1 and the pedigrees in figure 1. 
3.2. Muscle imaging 
Muscle imaging showed consistent involvement of calf muscles in all examined patients in 
Families 1–4. Younger patients with the mildest symptoms had fatty degenerative changes 
in gastrocnemius medialis and no other or only very mild involvement of soleus and 
semitendinosus muscles. The most severe changes were observed in F1 II:1 (Fig. 2) and 
F3 II:1 (not shown) who had degenerative fatty replacement in almost all posterior thigh 
and calf muscles. 
Muscle CT of the proband in Family 5 revealed fatty degenerative changes in almost all 
thigh muscles. Lower leg muscles showed diffuse involvement, most prominent in 
peroneus longus and tibialis posterior (Fig. 2). 
3.3. Muscle histology 
Muscle biopsies from the patients generally showed myofibrillar and rimmed-vacuolar 
pathology (table 1 and figure 3A–B). In electron microscopy, myofibrillar disruptions and 
autophagic rimmed vacuolar changes were evident in a biopsy from F1 II:1 (Fig. 3C–D). 
The biopsy from his daughter (F1 III:2) mostly showed mild fiber size variation and some 




internal nuclei (not shown). Immunofluorescence staining of the biopsy from F1 II:1 
showed rimmed vacuoles (Fig. 4) and myofibrillar protein accumulations staining positive 
for myotilin (not shown). Accumulation of DNAJB6, SQSTM1 (p62), TARDBP (TDP-43), 
and TIA1 was observed in the rimmed vacuolar fibers, as shown previously in patients with 
G/F domain DNAJB6 mutations [1,5,14,28]. 
3.4. Molecular genetics 
Targeted sequencing identified a DNAJB6 c.149C>T (p.A50V) mutation (Fig. 1) in all of 
the probands in families 1–4. In family 5, a DNAJB6 c.161A>C (p.E54A) variant was 
identified. The relatives in families 1, 2, 3, and 5 for whom DNA was available were Sanger 
sequenced, and the correct segregation of the disease mutations was confirmed in all four 
families. In the proband of F2 (II:1), also a c.410C>T variant (rs149027078, p.T137M, 
MAF=0.00009 in non-Finnish Europeans) in DNAJB6 was identified. This variant was also 
present in the healthy relatives F2 III:1 and III:2 and was therefore in trans with the 
c.149C>T change. 
3.5. DNAJB6 structure 
A homology model of the J and G/F domains of DNAJB6 (Fig. 5A) showed that the 
mutated residues A50 and E54 are located in the region of the J domain facing the G/F 
domain and are in close proximity with the previously identified F91 mutation site in the 
G/F domain. In contrast, the S57 residue, affected by the previously reported p.S57L 
variant [29] (see below) is not located in this interface. 
Protein sequence analysis indicated that the mutated residues are highly conserved in 
evolution. A50 was present in all the tetrapod DNAJB6 orthologs found from UniProt, and 
E54 in all vertebrates (Fig. 5B and online supplementary file 1). Overall, the C-terminal half 




of the J domain showed a high degree of conservation, and the same was true for the 12-
residue stretch containing all the published G/F domain mutations. 
3.6. Functional studies 
To test the effects of the novel mutations on DNAJB6b function, we investigated the 
mutant proteins in vitro. The original Finnish G/F-domain mutation p.F93L was included for 
comparison. We also analyzed the J-domain variant p.S57L, which has been previously 
reported in a single myopathic patient [29] but not studied functionally. 
In filter trap assay, the p.A50V and p.E54A mutations caused a significant loss of anti-
aggregation capacity towards 120Q-HTT, whereas p.S57L did not appear to affect this 
capacity (Fig. 6A and online supplementary file 2). The anti-aggregation activity of 
DNAJB6b towards polyglutamine clients has been shown to be a combination of J-
domain/HSPA-dependent and -independent functions [18]. To understand the effects of 
the disease-causing variants on these pathways, we studied the p.A50V and p.F93L 
variants in combination with p.H31Q, an HPD triad mutation that abolishes the interaction 
of the J domain with HSPA [30]. In 120Q-HTT filter trap assay, DNAJB6b harboring 
p.H31Q with either of the myopathy mutations showed significantly impaired anti-
aggregation activity compared to any of the mutations alone (Fig. 6B and online 
supplementary file 2). 
As a complementary approach, we studied the effects of DNAJB6 variants on TDP-43 
aggregation in heat-shocked cells. In this assay, all the J-domain variants as well as 
p.F93L similarly increased the proportion of cells showing nuclear TDP-43 accumulations 
(Fig. 6C and online supplementary file 3). DNAJB6b p.F93L performed more efficiently 
than the J-domain mutants in 120Q-HTT filter trap assay but comparably in the TDP-43 




assay, in line with the idea that anti-aggregation activity towards different client proteins 
involves different molecular mechanisms [18,31]. 
4. Discussion 
Mutations in the G/F domain of DNAJB6 are by now well-known causes of LGMD1D, and 
several mutations have been identified in populations from around the Northern 
hemisphere. Even though most mutations give rise to an adult-onset LGMD, some 
mutations cause distal onset myopathy [2,8,12,13]. We here describe novel disease-
causing mutations in the J domain of DNAJB6, thus expanding the region of myopathy 
mutations outside of the G/F domain encoded by exon 5. The two novel mutations result in 
a predominantly distal phenotype, with distal myopathy seen in the p.A50V patients, and 
more proximo-distal in the p.E54A family. 
The phenotype of p.A50V patients was very mild and late-onset, with symptoms starting in 
the calf muscles, and not all patients being even aware of the disease. With advanced 
age, however, the symptoms involved also proximal muscles, causing more disability. In 
the proband with the p.E54A mutation, the disease was more severe at younger age, 
encompassing proximal lower limb muscles from the beginning. One of our patients had 
moderately decreased pulmonary function but no respiratory symptoms; others had no 
respiratory findings which is consistent with majority of the earlier described DNAJB6 
patients [6]. Dysphagia has been reported in several DNAJB6-mutated patients and was 
present in one of the patients reported here. Cardiomyopathy has so far not been reported 
in any DNAJB6 patient, although DNAJB6 has been identified as a cardiomyopathy 
susceptibility gene [32]. 




On muscle biopsy, the findings from individuals with the novel J-domain mutations appear 
similar to those observed in G/F-domain mutation patients [1,5,14,28], with myofibrillar 
protein accumulations and at later stages rimmed vacuoles.  
The canonical J domain is the defining feature of J-protein co-chaperones and mediates 
their interaction with the HSPA chaperones. The mutated residues A50 and E54 are within 
the J domain but not in close proximity to the HPD motif required for HSPA binding [30]. 
The residues are, according to our structural homology model, located at the interface 
between the J and G/F domains, suggesting that the mutations interfere with interdomain 
interactions rather than protein-protein interactions. Interestingly, they both appear to 
interact with F91, a residue mutated in a severe form of LGMD1D [5,7]. This interface area 
has been suggested [6] to be important for proper function of DNAJB6. Our results are in 
line with this idea and may imply that the disease-causing mutations in the J and G/F 
domains act through a common downstream pathomechanism. Furthermore, the additive 
effect of p.H31Q and p.A50V on DNAJB6b polyQ anti-aggregation activity, and the lack of 
effect of p.H31Q compared to the other mutant constructs in the TDP-43 assay suggest 
that the myopathy-causing mutations do not simply inactivate the HSPA-dependent 
function of DNAJB6, but affect the HSPA-independent function. 
The c.149C>T (p.A50V) variant is reported once in gnomAD (rs575604496) [33]. As 
indicated above, due to late onset and mild symptoms this mutation can occur in younger 
individuals without subjective problems. Here we identified the p.A50V variant in four 
separate families using targeted sequencing and verified this finding as well as the 
segregation in all available family members with Sanger sequencing. Together with the 




functional effects observed with two independent methods, this indicates that p.A50V is a 
pathogenic variant and the cause of distal myopathy in these families. 
The c.161A>C (p.E54A) mutation is to date not found in any database. Pathogenicity of 
this variant is supported by our functional analyses where this variant behaved comparably 
to p.A50V. However, with segregation in just one small family it currently only reaches the 
criteria of likely pathogenic according to the ACMG guidelines [34]. 
The c.170C>T (p.S57L) variant was originally identified in a single LGMD patient [29], but 
later genetic analysis of family members revealed that this variant did not segregate with 
the disease (Savarese, personal communication). The variant is found in 3 of 243726 
alleles in gnomAD. The residue S57 is not located in the domain interface and mutation at 
this location will therefore probably not affect the interaction between the J and G/F 
domains. So far all experimentally tested G/F-domain mutations have shown loss of 
chaperone function in filter trap assay using 120Q-HTT, but p.S57L performed as 
efficiently as wild-type in this assay. In the TDP-43 assay, however, p.S57L behaved 
similarly to the other DNAJB6 variants analyzed. We hence cannot rule out that p.S57L 
can affect DNAJB6 function under some circumstances, and it should be considered as a 
variant of unknown significance. Nevertheless, our results indicate that p.S57L acts 
differently from the other J-domain mutations described here, and the lack of segregation 
strongly suggests that this variant is not the cause of disease in the original report [29]. 
Our findings expand the mutational spectrum from being restricted to the G/F domain and 
into the J domain and underline the importance of DNAJB6 mutations in distal myopathies. 
Mutations in DNAJB6 should therefore be considered not only in LGMD but also in other 
myopathies especially with aggregates and rimmed vacuolar pathology. 
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Fig. 1. Pedigrees of the five families. DNAJB6 variants segregated with the disease in 
families 1–5. Individuals for whom DNA was available are marked with *. The genetically 
tested family members are indicated as negative (–/–) or heterozygous (+/–) for the 
DNAJB6 variants c.149C>T (p.A50V, in F1–4) or c.161A>C (p.E54A, in F5). 
 
 
Fig. 2. Muscle imaging. (A) Patient F3 III:2 at age 39. Moderate fatty degenerate changes 
are seen in gastrocnemius medialis muscle more on the right and mild in semitendinosus 
muscle. (B) Patient F4 II:1 at age 52. Severe involvement in all calf muscles and milder in 




hamstrings. (C) Patient F1 II:1 at age 75. Severe changes are seen in all calf muscles 
symmetrically and peroneus longus on the left. Hamstring muscles are also severely 
affected with less involvement in vastii muscles. Rectus femoris is best spared muscle. (D) 
Patient F5 II:2 at age 35. Severe involvement in anterior and posterior thigh muscles and 
diffuse fatty degenerative changes in all lower leg muscles, most prominent in peroneus 
longus and tibialis posterior. 
 
 
Fig. 3. Muscle pathology. (A–B) Serial sections of a muscle biopsy from patient F3 II:1 in 
hematoxylin/eosin (A) and modified Gomori trichrome stainings (B), showing myofibrillar 
and rimmedvacuolar pathology. (C–D) Electron micrographs of a muscle biopsy from 
patient F1 II:1 showing Z-disk disruption and protein accumulations (C), and vacuolar 
pathology (D). Scale bar = 2 μm. 
 





Fig. 4. Immunofluorescence microscopy. Immunofluorescence images of a muscle biopsy 
from patient F1 II:1 showing DNAJB6, SQSTM1, TIA1, and TARDBP in protein 
accumulations as seen also with G/F-domain mutations in DNAJB6. Scale bar = 100 μm. 
 





Fig. 5. Structural analysis of DNAJB6 mutations. (A) Protein homology model showing 
predicted location of residues A50, E54, S57, and F91. The region coded for by exon 5 
(G/F domain) is shown in blue and the J domain in orange. A50 and E54 are located close 
to F91 in the interface between the J- and G/F-domains, whereas S57 is not in this area. 
(B) Protein sequence alignment of selected vertebrate DNAJB6 orthologs, showing 
conservation of the A50 and E54 residues. For the full alignment, see online 
supplementary file 1. 
 
  





Fig. 6. Impaired function of mutant DNAJB6b. (A) Filter-trap assay showed significant loss 
of 120Q-HTT anti-aggregation activity for p.A50V and p.E54A, but not p.S57L, compared 
to wild-type DNAJB6b. The previously described p.F93L variant is included as reference 
and wild-type DNAJB6a (inactive towards cytoplasmic aggregation) as a negative control. 
Induction delay 5 h. (B) The p.H31Q mutation showed an additive impairing effect on 
DNAJB6b anti-aggregation activity towards 120Q-HTT when combined with p.A50V in 
filter-trap assay. Induction delay 4 h. Bars show mean ± SD of aggregation score (ratio of 
aggregated/soluble 120Q-HTT in induced versus uninduced cells) of 9 (A) or 12 (B) 
replicates. Representative FTA membranes show aggregated 120Q-HTT (in technical 
duplicates), whereas western blots show soluble 120Q-HTT and V5-DNAJB6 in uninduced 
(–) and induced (+) cells. For all FTA and WB images, see online supplementary file 2. (C) 
All investigated DNAJB6b variants (p.A50V, p.E54A, p.S57L, and p.F93L) increased 
nuclear TDP-43 aggregation after heat shock, whereas wild-type and p.H31Q DNAJB6b 
and GFP had no such effect. Bars show the percentage of cells with TDP-43 
accumulations (mean ± SD) in 8 replicates. Representative cell images of DNAJB6b wild-
type and p.A50V are shown under the graph; see online supplementary file 3 for the full 




series of representative images. *p<0.05, **p<0.01, ***p<0.001 compared to wild-type 
DNAJB6b (A, C) or for the indicated pairs (B). 












Muscle weakness CK level EMG Muscle 
biopsy 
Muscle imaging Other 
F1  
II:1 
M/75 69 Distal 
weakness 
Distal LL (anterior and 
posterior compartment), mild in 
proximal LL, very mild in UL 




Glat, S, PL (left), 
hamstrings 
Moderate: vastii 
COPD, no cardiac 
symptoms 
III:2 F/50 n.a. Distal 
weakness 







F/65 40 Distal lower 
leg weakness 
 












M/70 40 Waddling gait Distal and proximal LL, distal 
UL, mild dysphagia ; ambulant 
500 m with/without cane 













*age at death 
COPD, chronic obstructive pulmonary disease; ECG, electrocardiography; EDB, extensor digitorum brevis; FEV1, forced expiratory volume in 
one second; FVC,  forced vital capacity; Glat, gastrocnemius lateralis; Gmed, gastrocnemius medialis; n.a., not available; LL, lower limbs; PL, 
peroneus longus; RV, rimmed vacuoles; S, soleus; UL, upper limbs; VC, vital capacity 
III:2  
 
M/39 n.a. n.a. No clear weakness but limping 
gait 





M/52 47 Difficulty 
walking on 
toes 
Distal LL with muscle atrophy 
in EDB and calf muscles 




FEV1 78%,  







n.a. Lower limb 
muscle 
weakness 
Mild distal and proximal, 
dysarthria 
n.a. n.a. n.a. n.a.  
III:2 M/51 20 Difficulty 
walking 
Distal and proximal with diffuse 
muscle atrophy, Achilles 
tendon contractures 
213 Small motor 
units, fibrillation, 
fasciculations 
RV Diffuse in thigh 
and leg muscles 
(prox>dist) 
ECG normal, no 
cardiac symptoms 
         
